These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 14718137)

  • 1. [Palivizumab prophylaxis against respiratory syncytial virus. Should its indications be reviewed?].
    Salas Hernández S
    An Pediatr (Barc); 2004 Jan; 60(1):87-8. PubMed ID: 14718137
    [No Abstract]   [Full Text] [Related]  

  • 2. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: a note of caution.
    Suresh S; Schilling S; Dakin C; Harris MA
    J Paediatr Child Health; 2003 Nov; 39(8):637. PubMed ID: 14629536
    [No Abstract]   [Full Text] [Related]  

  • 3. Prophylaxis against respiratory syncytial virus in premature infants. IMpact-RSV Study Group.
    Top FH; Connor EM; Carlin DA
    Lancet; 2000 Mar; 355(9208):1014. PubMed ID: 10768456
    [No Abstract]   [Full Text] [Related]  

  • 4. Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates.
    Gortner L
    Klin Padiatr; 2017 Sep; 229(5):259-260. PubMed ID: 28926860
    [No Abstract]   [Full Text] [Related]  

  • 5. Who shall not receive palivizumab?
    Brunvand L; Lindemann R; Grøgaard J
    Pediatrics; 2000 Oct; 106(4):866. PubMed ID: 11183179
    [No Abstract]   [Full Text] [Related]  

  • 6. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.
    Vogel AM; Lennon DR; Broadbent R; Byrnes CA; Grimwood K; Mildenhall L; Richardson V; Rowley S
    J Paediatr Child Health; 2002 Dec; 38(6):550-4. PubMed ID: 12410864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.
    Curtiss FR; Fairman KA
    J Manag Care Pharm; 2010; 16(1):59-66. PubMed ID: 20044846
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoprophylaxis for respiratory syncytial virus.
    Sánchez PJ
    Pediatr Infect Dis J; 2002 May; 21(5):473-8. PubMed ID: 12150195
    [No Abstract]   [Full Text] [Related]  

  • 11. A survey of palivizumab for infants with cystic fibrosis in the UK.
    McCormick J; Southern KW
    Arch Dis Child; 2007 Jan; 92(1):87-8. PubMed ID: 17185451
    [No Abstract]   [Full Text] [Related]  

  • 12. [Recommendations for the prevention of respiratory syncytial virus in high-risk pediatric groups].
    Janković B; Minić P; Maglajlić-Djukić S; Prekajski N
    Vojnosanit Pregl; 2009 Oct; 66(10):827-9. PubMed ID: 19938762
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prevention of respiratory syncytial virus infections with palivizumab].
    Ellingsen BB; Aase SA; Øymar K
    Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
    [No Abstract]   [Full Text] [Related]  

  • 14. Case management for pediatric respiratory syncytial virus outcomes.
    Deming LM
    Case Manager; 2002; 13(4):72-4. PubMed ID: 12131912
    [No Abstract]   [Full Text] [Related]  

  • 15. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric case management for respiratory syncytial virus outcomes.
    Rieve JA
    Case Manager; 2002; 13(2):32-4. PubMed ID: 11901367
    [No Abstract]   [Full Text] [Related]  

  • 17. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida.
    Hampp C; Saidi AS; Winterstein AG
    J Pediatr; 2010 Jun; 156(6):953-959.e1. PubMed ID: 20223478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palivizumab for preterm infants. Is it worth it?
    Embleton ND; Harkensee C; Mckean MC
    Arch Dis Child Fetal Neonatal Ed; 2005 Jul; 90(4):F286-9. PubMed ID: 16036888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
    Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
    Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palivizumab (Synagis) for prevention of respiratory illness in children.
    MacConnachie AM
    Intensive Crit Care Nurs; 2000 Apr; 16(2):123-4. PubMed ID: 11868587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.